We are live on !
Find out more
Perceptive Advisors Portfolio holdings
AUM
$6.66B
Turnover
32.23%
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter Est. Return
+32.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,270.13%
10 Year Est. Return
+54,096.87%
AUM
$6.66B
AUM Growth
+$1.54B
(+30%)
Cap. Flow
+$235M
Cap. Flow % of AUM
Cap. Flow %
3.53%
Top 10 Holdings %
Top 10 Hldgs %
47.3%
Holding
121
New
27
Increased
30
Reduced
28
Closed
12
Avg Time Held
Equity + Options
1.3
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
1.4
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KARD
Kardigan Inc
KARD
|
+$190M |
| 2 |
Avalyn Pharma
AVLN
|
+$77.2M |
| 3 |
Tango Therapeutics
TNGX
|
+$63.5M |
| 4 |
Relay Therapeutics
RLAY
|
+$63.2M |
| 5 |
Biogen
BIIB
|
+$52.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$209M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$85.9M |
| 3 |
Day One Biopharmaceuticals
DAWN
|
+$37.6M |
| 4 |
Dyne Therapeutics
DYN
|
+$36.8M |
| 5 |
Abivax
ABVX
|
+$28.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.3% |
| 2 | Miscellaneous | 3.58% |
| 3 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
PUT
Moderna
MRNA
$79.9B
| $70M | 1.05% |
1,000,000
| – | – |
2026 Q1
1 quarter
|
|
|
27
Dyne Therapeutics
DYN
$2.92B
| $59.7M | 0.9% |
2,689,235
-1,979,604
| -42% | -$36.8M |
2024 Q3
7 quarters
|
|
|
28
Biogen
BIIB
$37B
| $59.7M | 0.9% |
+276,173
| New | +$52.8M |
2026 Q2
0 quarters
|
|
29
Immunovant
IMVT
$5.87B
| $52.3M | 0.79% |
1,357,383
-240,000
| -15% | -$7.31M |
2022 Q4
14 quarters
|
|
30
UnitedHealth
UNH
$375B
| $48.5M | 0.73% |
+116,806
| New | +$43.3M |
2026 Q2
0 quarters
|
|
31
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $47.5M | 0.71% |
+300,000
| New | +$40.6M |
2026 Q2
0 quarters
|
|
32
Ionis Pharmaceuticals
IONS
$7.13B
| $44.9M | 0.67% |
566,000
+62,000
| +12% | +$4.67M |
2026 Q1
1 quarter
|
|
33
Sutro Biopharma
STRO
$155M
| $43.3M | 0.65% |
1,304,846
+589,539
| +82% | +$18.4M |
2026 Q1
1 quarter
|
|
34
Alto Neuroscience
ANRO
$862M
| $42.5M | 0.64% |
1,609,893
-400,000
| -20% | -$9.25M |
2025 Q3
3 quarters
|
|
35
Jazz Pharmaceuticals
JAZZ
$13.9B
| $41M | 0.61% |
170,000
| – | – |
2025 Q4
2 quarters
|
|
36
Corvus Pharmaceuticals
CRVS
$886M
| $39.9M | 0.6% |
2,667,441
+375,000
| +16% | +$5.2M |
2025 Q2
4 quarters
|
|
37
Sionna Therapeutics
SION
$163M
| $39.8M | 0.6% |
905,000
+246,561
| +37% | +$9.9M |
2025 Q1
5 quarters
|
|
38
CytomX Therapeutics
CTMX
$506M
| $39.1M | 0.59% |
10,439,185
+340,361
| +3% | +$1.3M |
2025 Q2
4 quarters
|
|
39
Artivion
AORT
$1.14B
| $39M | 0.59% |
1,737,290
+100,000
| +6% | +$2.8M |
2021 Q4
18 quarters
|
|
40
X4 Pharmaceuticals
XFOR
$321M
| $37M | 0.56% |
7,933,491
+1,195,843
| +18% | +$4.91M |
2025 Q4
2 quarters
|
|
41
Corcept Therapeutics
CORT
$9.28B
| $34.6M | 0.52% |
398,385
+348,385
| +697% | +$21M |
2026 Q1
1 quarter
|
|
42
Repligen
RGEN
$11.2B
| $33.9M | 0.51% |
248,212
-32,329
| -12% | -$3.97M |
2025 Q1
5 quarters
|
|
43
Anteris Technologies
AVR
$572M
| $33.7M | 0.51% |
3,425,476
| – | – |
2024 Q4
6 quarters
|
|
44
Rapport Therapeutics
RAPP
$1.24B
| $32.2M | 0.48% |
773,342
+99,419
| +15% | +$3.65M |
2025 Q3
3 quarters
|
|
|
DMRA
45
Damora Therapeutics
DMRA
$1.3B
| $31.8M | 0.48% |
1,223,000
| – | – |
2026 Q1
1 quarter
|
|
46
Charles River Laboratories
CRL
$16.5B
| $31.8M | 0.48% |
+140,000
| New | +$24.9M |
2026 Q2
0 quarters
|
|
47
Axsome Therapeutics
AXSM
$7.6B
| $29M | 0.44% |
118,450
-31,500
| -21% | -$6.83M |
2023 Q2
12 quarters
|
|
48
PUT
EyePoint Inc
EYPT
$34.9M
| $28.6M | 0.43% |
+2,000,000
| New | +$26.8M |
2026 Q2
0 quarters
|
|
49
DBV Technologies S.A. American Depositary Shares
DBVT
$613M
| $27.1M | 0.41% |
1,653,350
+688,959
| +71% | +$13M |
2026 Q1
1 quarter
|
|
50
iRhythm Holdings
IRTC
$4B
| $26.6M | 0.4% |
223,766
+118,740
| +113% | +$13.8M |
2025 Q3
3 quarters
|
|
Similar funds
Perceptive Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Perceptive Advisors held 121 positions worth $6.66B, up 30% from $5.12B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Perceptive Advisors deployed $235M of net new capital in Q2 2026, opening 27 new positions and adding to 30 existing holdings. Its largest new stake was Kardigan Inc: 8,200,662 shares worth $196M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $85.9M trimmed.
- Perceptive Advisors's largest Q2 2026 buy was Kardigan Inc: 8,200,662 shares worth $196M.
- Perceptive Advisors added most to Tango Therapeutics in Q2 2026, an estimated $63.5M increase.
- Perceptive Advisors's biggest Q2 2026 reduction was Ascendis Pharma A/S, cutting an estimated $85.9M.
- Perceptive Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $209M.
- Perceptive Advisors's ten largest holdings make up 47% of its $6.66B portfolio in Q2 2026.
- Perceptive Advisors opened 27 new positions and closed 12 in Q2 2026.
- Perceptive Advisors's portfolio value rose 30% quarter-over-quarter to $6.66B.
Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.